126002-14-0

Basic information

• Product Name: Formamide, N-[2-(4-methoxyphenyl)-1-methylethyl]-
• CAS NO: 126002-14-0
• Molecular Formula: C11H15NO2
• Molecular Weight: 193.246
• Mol File: 126002-14-0.mol

Chemical Properties

• CAS DataBase Reference: Formamide, N-[2-(4-methoxyphenyl)-1-methylethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Formamide, N-[2-(4-methoxyphenyl)-1-methylethyl]-(126002-14-0)
• EPA Substance Registry System: Formamide, N-[2-(4-methoxyphenyl)-1-methylethyl]-(126002-14-0)

Safety Data

• Hazardous Substances Data: 126002-14-0(Hazardous Substances Data)

Upstream product

• 122-84-9 4-methoxybenzyl methyl ketone 
• 77287-34-4 formamide 
• 64-13-1 2-amino-1-(4-methyoxyphenyl)propane 
• 109-94-4 formic acid ethyl ester 
• 97424-75-4 1,2-diacetoxy-1-(4-methoxy-phenyl)-propane 
• 123-11-5 4-methoxy-benzaldehyde 
• 17354-63-1 4-(2-nitro-propenyl)-anisole 
• 64-18-6 formic acid 

Downstream Products

• 64-13-1 2-amino-1-(4-methyoxyphenyl)propane 
• 22331-70-0 p-Methoxymethamphetamine 

Relevant articles and documents

Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action

Chronic hepatitis B virus (HBV) infection is a serious public health burden, and current therapies cannot achieve satisfactory cure rate. There are high unmet medical needs of novel therapeutic agents with differentiated mechanism of action (MOA) from the

Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.

NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula (I) wherein R1, R2 R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds in the treatment of the hepatitis B virus.

(2,S)-1-(4-Methoxyphenyl)-N-[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-2-propanamine in Crude p-Methoxyamphetamine (PMA) Produced by the Leuckart Method

The synthesis and separation of both diastereoisomers of 1-(4-methoxyphenyl)-N-[2-(4-methoxyphenyl)-1-methylethyl]-2-propanamine as markers of clandestine p-methoxyamphetamine have been described. The stereochemistry of the meso diastereomer was established by crystallographic method.

N-(α-alkylbenzylidene)-α-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor

There is disclosed an N-(α-alkylbenzylidene)-α-phenylalkylamine represented by the general formula (1): STR1 wherein R1 represents a lower alkyl group, R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group and X represents a halogen atom or a lower alkoxy group, its use and a process for producing the same and processes for producing intermediates therefor.

POTENTIAL ANTIDEPRESSANTS: 1-(4-(AMINOALKOXY)PHENYL)-2-PROPYLAMINES

1-(4-Hydroxyphenyl)-2-propylamine (X) and its N-monomethyl (XI) and N,N-dimethyl (XII) derivatives were O-alkylated with six tert.aminoalkyl chlorides to aminoalkyl ethers Ia-VIc.In cases of X and XI the reactions were complicated by O,N-dialkylation leading to isolation of triamino ethers XVI and XVII. 1-(4-Hydroxyphenyl)propan-2-one was alkylated with 2-dimethylaminoethyl chloride and the ether XIII was obtained.An attempt to transform 4-(2-dimethylaminoethoxy)benzaldehyde to the 1-aryl-2-nitropropene XIV by heating with nitroethane in acetic acid in the presence of ammonium acetate resulted in the formation of 4-(2-dimethylaminoethoxy)benzonitrile (XV).In the form of salts the amino ethers prepared were tested for antidepressant activity but proved little active or inactive.